Stoke Therapeutics, Inc. (STOK) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.55B USD. 52-week range 20.32 to 40.22 USD. Trailing P/E 48.8. Data as of 2026-10-09.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational ...